Global Dravet Syndrome Market

Global Dravet Syndrome Market Size, Share, Growth Analysis, By Diagnosis(MRI, EEG), By Treatment and Management(Seizure medications, A ketogenic diet), By Type(Pharmaceutical Companies, Hospitals) - Industry Forecast 2024-2031

Report ID: SQMIG35A2815 | Region: Global | Published Date: April, 2024
Pages: 219 | Tables: 92 | Figures: 67

Share your requirements to help us to customize the report.
   I acknowledge that I have read the Privacy Policy
Confidentiality

We respect your privacy rights and safeguard your personal information. We prevent the disclosure of personal information to third parties.

Analyst Support
$5,300
BUY NOW GET FREE SAMPLE

FAQs

Global Dravet Syndrome Market size was valued at USD 343.85 million in 2022 and is poised to grow from USD 376.17 million in 2023 to USD 771.84 million by 2031, growing at a CAGR of 9.4% in the forecast period (2024-2031).

The competitive environment of the global Dravet Syndrome market is dynamic and characterized by the presence of a mix of well-established brands, emerging players, and niche producers. Innovation is a key competitive factor. 'SK Biopharmaceuticals', 'Biocodx', 'Upsher Smith Laboratories, LLC.', 'Encoded Therapeutics Inc.', 'GW Research Ltd.', 'UCB S.A.', 'Zogenix', 'Supernus Pharmaceuticals', 'Epygenix Therapeutics, Inc.,', 'Ovid Therapeutics Inc.', 'Takeda Pharmaceutical Company Limited.'

Genetic mutations, especially SCN1A gene mutations, contribute significantly to the onset of Dravet syndrome in children, with approximately 80-90% of cases associated with mutations in this gene in this tissue specifically this related Advancement in genetic testing technology is expected to drive market revenue growth of testing methods. If applied, such as dual detection, deletion, mosaicism, and other methods a sophisticated diagnostic approach will play an important role in the accurate and efficient diagnosis of genetic abnormalities associated with Dravet syndrome.

Recent developments in regulatory approvals have played an important role in driving the Dravet Syndrome project forward. Notably, withdrawal from medications such as stiripentol (Diacomit) and Epidiolex have been extremely helpful in managing and treating the symptoms associated with the disorder. These regulatory veins mark important points landmark in dealing with the severe complications of Dravet syndrome. Furthermore, expectations of upcoming regulatory approvals, exemplified by Zogenix’s New Drug Application (NDA) submission for its clinical candidate ZX008 (Fintepla), are expected to fuel the rapid expansion of the market.

Market trends for specific industries highlight North America as the dominant region, exhibiting the greatest impact, followed by Europe and Asia Pacific Key market players are actively directing their efforts towards developing new drugs and therapies development, using various strategies to strengthen their market position. The competitive environment is characterized by a proactive approach in leading organizations, which engage in ongoing R&D activities to come up with innovative solutions. These strategic initiatives not only contribute to the expansion of the market but also enhance the competitive edge of the major competitors.

Related Reports

Hospital Consumables Market
Buy Now GET FREE SAMPLE
Global Vascular Grafts Market
Buy Now GET FREE SAMPLE
Breath Analyzers Market
Buy Now GET FREE SAMPLE
Veterinary Artificial Insemination Market
Buy Now GET FREE SAMPLE

Feedback From Our Clients

Global Dravet Syndrome Market

Product ID: SQMIG35A2815

$5,300
BUY NOW GET FREE SAMPLE